Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

2.

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.

Li Z, Block MS, Vierkant RA, Fogarty ZC, Winham SJ, Visscher DW, Kalli KR, Wang C, Goode EL.

Tumour Biol. 2016 Oct;37(10):13279-13286. doi: 10.1007/s13277-016-5163-2. Epub 2016 Jul 26.

3.

Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.

Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, Lee JH, Choi KU.

World J Surg Oncol. 2012 Sep 17;10:193. doi: 10.1186/1477-7819-10-193.

4.

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ.

PLoS One. 2014 Jun 30;9(6):e100816. doi: 10.1371/journal.pone.0100816. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e108833.

5.

High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer.

Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T.

Br J Cancer. 2010 Mar 2;102(5):908-15. doi: 10.1038/sj.bjc.6605558. Epub 2010 Feb 9.

6.

CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.

Bösmüller HC, Wagner P, Pham DL, Fischer AK, Greif K, Beschorner C, Sipos B, Fend F, Staebler A.

Int J Gynecol Cancer. 2017 Feb;27(2):239-245. doi: 10.1097/IGC.0000000000000888.

PMID:
27984374
7.

Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients.

Ma FJ, Liu ZB, Hu X, Ling H, Li S, Wu J, Shao ZM.

PLoS One. 2014 Oct 31;9(10):e111639. doi: 10.1371/journal.pone.0111639. eCollection 2014.

8.

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM.

BMC Cancer. 2018 Oct 11;18(1):970. doi: 10.1186/s12885-018-4880-x.

9.

Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells.

Wang AC, Su QB, Wu FX, Zhang XL, Liu PS.

Eur J Clin Invest. 2009 Feb;39(2):157-64. doi: 10.1111/j.1365-2362.2008.02070.x.

PMID:
19200169
10.

Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.

Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, Ferreira Seiva FR, Martinez M, Fávaro WJ, Domeniconi RF, Pinheiro PF, Delazari Dos Santos L, Martinez FE.

BMC Cancer. 2015 Feb 6;15:34. doi: 10.1186/s12885-015-1032-4.

11.

Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.

Zhu Y, Huang JM, Zhang GN, Zha X, Deng BF.

J Transl Med. 2012 Apr 25;10:77. doi: 10.1186/1479-5876-10-77.

12.

Significance of TLR4/MyD88 expression in breast cancer.

Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):7034-9. eCollection 2015.

13.

Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.

Liu H, Zhang G, Huang J, Ma S, Mi K, Cheng J, Zhu Y, Zha X, Huang W.

J Transl Med. 2016 Apr 27;14(1):104. doi: 10.1186/s12967-016-0845-5.

14.

TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL.

Oncogene. 2009 Dec 10;28(49):4353-63. doi: 10.1038/onc.2009.289.

15.

P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.

de Almeida Chuffa LG, de Moura Ferreira G, Lupi LA, da Silva Nunes I, Fávaro WJ.

J Ovarian Res. 2018 Jan 17;11(1):8. doi: 10.1186/s13048-018-0380-5.

16.

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE.

Br J Cancer. 2014 Dec 9;111(12):2297-307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30.

17.

Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.

McGrath SE, Annels N, Madhuri TK, Tailor A, Butler-Manuel SA, Morgan R, Pandha H, Michael A.

BMC Cancer. 2018 Oct 3;18(1):943. doi: 10.1186/s12885-018-4816-5.

18.

TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells.

Wu K, Zhang H, Fu Y, Zhu Y, Kong L, Chen L, Zhao F, Yu L, Chen X.

Mol Med Rep. 2018 Sep;18(3):3411-3420. doi: 10.3892/mmr.2018.9326. Epub 2018 Jul 26.

19.

WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.

Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A.

BMC Cancer. 2006 Apr 11;6:90.

Supplemental Content

Support Center